Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Cash per Share : €0.26 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Laboratorios Farmaceuticos Rovi's Cash per Share for the quarter that ended in Mar. 2024 was €0.26.

Laboratorios Farmaceuticos Rovi Cash per Share Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Cash per Share Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

1.22

0.96

1.81

2.39

0.49

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															2.70	2.91	1.06	0.49	0.26

Laboratorios Farmaceuticos Rovi Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Laboratorios Farmaceuticos Rovi's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	25.322	/	51.8
	=	0.49

Laboratorios Farmaceuticos Rovi's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	13.085	/	51.3
	=	0.26

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Laboratorios Farmaceuticos Rovi Cash per Share Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.